We are passionate about developing novel therapies for patients with serious metabolic diseases that lack effective treatment options.
We began with an engineered protein called efruxifermin (EFX), which we licensed from Amgen and are developing for treatment of non-alcoholic steatohepatitis (NASH). NASH is a serious liver disease caused by metabolic dysregulation that does not have any approved therapies. EFX is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body.
We believe our clinical trial data, which include some of the largest and most consistent effects reported to date in the NASH space, position EFX to be a potentially best-in-class treatment, if approved, for NASH.
Our corporate headquarters is located in South San Francisco, California, but our employees are spread throughout the country. We believe in hiring the best talent and recognize that great work doesn’t depend on reporting daily to a central office.